Safety, tolerability, pharmacokinetic and pharmacodynamic effects of single and multiple escalating doses of ODM-108: a single centre study in healthy male volunteers. - ODM-108 SAD and MAD study.

Orion Corporation Orion Pharma0 sites206 target enrollmentTBD

Conditionseuropathische pijn.Nerve damage pain.

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: europathische pijn.
Sponsor: Orion Corporation Orion Pharma
Enrollment: 206
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

Orion Corporation Orion Pharma

Eligibility Criteria

Inclusion Criteria

•Healthy male volunteers
•18 \- 55 years, inclusive
•BMI 18 \- 30 kilograms/meter2
•Weight 55 \- 95 kilograms, inclusive

Exclusion Criteria

•Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1\.5 liters of blood in the 10 months prior the start of this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting

Not Applicable

Safety, tolerability, pharmacokinetic and pharmacodynamic effects of single and multiple escalating doses of ODM-111 and effect of food on the pharmacokinetics of ODM-111 and pharmacokinetic drug-drug interaction potential of ODM-111Chronic-/neuropathic pain10029305

NL-OMON53911Orion Corporation182

Active, not recruiting

Phase 1

A study on the safety and effectiveness of the new investigational drug ODM-111 when given to healthy volunteers, and how ODM-111 is absorbed and processed by the human body.ovel treatment against chronic-/neuropathic pain.Nervous System Diseases

ISRCTN84512888Orion Corporation (Finland)148

Active, not recruiting

Phase 1

A research study of how a new medicine NNC0365-3769 (Mim8) works in the body of healthy people and patients with bleeding disorder

EUCTR2019-000465-20-ATovo Nordisk A/S94

Active, not recruiting

Phase 1

Safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple subcutaneous doses of NNC0365-3769 (Mim8) in healthy subjects and in subjects with haemophilia A with or without factor VIII inhibitors (NN7769-4513)severe haemophilia A with or without FVIII inhibitors

JPRN-jRCT2031200136Tsuchiyama Akio82

Active, not recruiting

Phase 1

A research study of how a new medicine NNC0365-3769 (Mim8) works in the body of healthy people and patients with bleeding disorderHealthy volunteers (Haemophilia A with or without inhibitors)Haemophilia AHaemophilia A with inhibitorsMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

EUCTR2019-000465-20-GBovo Nordisk A/S82